-
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
•
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I/II study for its novel antibody drug conjugate (ADC) cancer therapy, OBI-992, which targets TROP2. The antibody molecules utilized in the development of…
-
Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China
•
Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions in China, has entered into a strategic partnership with French bioprocessing company Verdot. The collaboration, facilitated by Cathay Capital, will position Bio-Link as the primary distributor of Verdot’s innovative chromatography columns within the Chinese market.…
-
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
•
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and…
-
Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications
•
Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S. giant Illumina (NASDAQ: ILMN) to localize the iScan high-end chip scanners. This collaboration aims to harness their technological strengths and resources to enhance the application of genomics in precision health management, with a particular focus…
-
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to acquire Ambrx Biopharma (NASDAQ: AMAM), a U.S.-based developer of antibody drug conjugates (ADCs). The deal is valued at approximately USD 2 billion in equity and carries a net cash requirement of USD 1.9 billion, with…
-
MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human papillomavirus (HPV) 9-valent vaccine, Gardasil 9. The vaccine is now approved for a two-dose vaccination schedule (0,…
-
Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies
•
The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted by Astellas (TYO: 4503), a Japanese pharmaceutical company, for its first-in-class anti-CLDN18.2 biologic zolbetuximab. The drug was under consideration for the treatment of locally advanced unresectable or metastatic HER2-negative CLDN18.2-positive gastric or gastroesophageal junction (GEJ)…
-
3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment
•
3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its over-the-counter (OTC) drug, a 5% minoxidil foam agent, which is indicated for the treatment of male pattern hair loss and alopecia areata.…
